Recent Developments in Radiotherapy

被引:317
作者
Citrin, Deborah E. [1 ]
机构
[1] NCI, Radiat Oncol Branch, Ctr Canc Res, Bldg 10, Bethesda, MD 20892 USA
关键词
CELL LUNG-CANCER; MODULATED RADIATION-THERAPY; ELECTIVE NODAL IRRADIATION; INVOLVED-FIELD RADIATION; CALRETICULIN EXPOSURE; LOCAL RADIATION; STAGE-I; PHYSIOLOGICAL FRAILTY; BREAST RADIOTHERAPY; SECRETORY PHENOTYPE;
D O I
10.1056/NEJMra1608986
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
It is estimated that 470,000 patients receive radiotherapy each year in the United States. 1 As many as half of patients with cancer will receive radiotherapy. 2 Improvements in diagnosis, therapy, and supportive care have led to increasing numbers of cancer survivors. 3 In response, the emphasis of radiation oncology has expanded beyond cure to include reducing side effects, particularly late effects, which may substantially affect a patient's quality of life. Radiotherapy is used to treat benign and malignant diseases and can be used alone or in combination with chemotherapy, surgery, or both. For primary tumors or metastatic deposits, palliative radiotherapy is often used to reduce pain or mass effect (due to spinal cord compression, brain metastases, or airway obstruction). Therapeutic radiation can be delivered from outside the patient, known as external-beam radiation therapy, or EBRT (see the Glossary in the Supplementary Appendix, available with the full text of this article at NEJM.org), by implanting radioactive sources in cavities or tissues (brachytherapy), or through systemic administration of radiopharmaceutical agents. Multiple technological and biologic advances have fundamentally altered the field of radiation oncology since it was last reviewed in the Journal.(4)
引用
收藏
页码:1065 / 1075
页数:11
相关论文
共 69 条
  • [1] [Anonymous], 2012, FRONT ONCOL
  • [2] [Anonymous], 2012, CANC TREATM SURV FAC
  • [3] Antitransforming growth factor-β antibody 1D11 ameliorates normal tissue damage caused by high-dose radiation
    Anscher, MS
    Thrasher, B
    Rabbani, Z
    Teicher, B
    Vujaskovic, Z
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 65 (03): : 876 - 881
  • [4] Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy
    Apetoh, Lionel
    Ghiringhelli, Francois
    Tesniere, Antoine
    Obeid, Michel
    Ortiz, Carla
    Criollo, Alfredo
    Mignot, Gregoire
    Maiuri, M. Chiara
    Ullrich, Evelyn
    Saulnier, Patrick
    Yang, Huan
    Amigorena, Sebastian
    Ryffel, Bernard
    Barrat, Franck J.
    Saftig, Paul
    Levi, Francis
    Lidereau, Rosette
    Nogues, Catherine
    Mira, Jean-Paul
    Chompret, Agnes
    Joulin, Virginie
    Clavel-Chapelon, Francoise
    Bourhis, Jean
    Andre, Fabrice
    Delaloge, Suzette
    Tursz, Thomas
    Kroemer, Guido
    Zitvogel, Laurence
    [J]. NATURE MEDICINE, 2007, 13 (09) : 1050 - 1059
  • [5] Physiologic Frailty in Nonelderly Hematopoietic Cell Transplantation Patients Results From the Bone Marrow Transplant Survivor Study
    Arora, Mukta
    Sun, Can-Lan
    Ness, Kirsten K.
    Teh, Jennifer Berano
    Wu, Jessica
    Francisco, Liton
    Armenian, Saro H.
    Schad, Amy
    Namdar, Golnaz
    Bosworth, Alysia
    Kuo, Linus
    Weisdorf, Daniel J.
    Forman, Stephen J.
    Bhatia, Smita
    [J]. JAMA ONCOLOGY, 2016, 2 (10) : 1277 - 1286
  • [6] Naturally occurring p16Ink4a-positive cells shorten healthy lifespan
    Baker, Darren J.
    Childs, Bennett G.
    Durik, Matej
    Wijers, Melinde E.
    Sieben, Cynthia J.
    Zhong, Jian
    Saltness, Rachel A.
    Jeganathan, Karthik B.
    Verzosa, Grace Casaclang
    Pezeshki, Abdulmohammad
    Khazaie, Khashayarsha
    Miller, Jordan D.
    van Deursen, Jan M.
    [J]. NATURE, 2016, 530 (7589) : 184 - +
  • [7] Development of the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
    Basch, Ethan
    Reeve, Bryce B.
    Mitchell, Sandra A.
    Clauser, Steven B.
    Minasian, Lori M.
    Dueck, Amylou C.
    Mendoza, Tito R.
    Hay, Jennifer
    Atkinson, Thomas M.
    Abernethy, Amy P.
    Bruner, Deborah W.
    Cleeland, Charles S.
    Sloan, Jeff A.
    Chilukuri, Ram
    Baumgartner, Paul
    Denicoff, Andrea
    St Germain, Diane
    O'Mara, Ann M.
    Chen, Alice
    Kelaghan, Joseph
    Bennett, Antonia V.
    Sit, Laura
    Rogak, Lauren
    Barz, Allison
    Paul, Diane B.
    Schrag, Deborah
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2014, 106 (09):
  • [8] The Missing Voice of Patients in Drug-Safety Reporting
    Basch, Ethan
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (10) : 865 - 869
  • [9] Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer
    Bradley, J
    Thorstad, WL
    Mutic, S
    Miller, TR
    Dehdashti, F
    Siegel, BA
    Bosch, W
    Bertrand, RJ
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 59 (01): : 78 - 86
  • [10] The Tumor Radiobiology of SRS and SBRT: Are More Than the 5 Rs Involved?
    Brown, J. Martin
    Carlson, David J.
    Brenner, David J.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 88 (02): : 254 - 262